| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANAB | Common Stock | Options Exercise | $41,044 | +36,646 | +54% | $1.12* | 104,282 | 01 Nov 2021 | Direct | |
| transaction | ANAB | Common Stock | Sale | $1,099,967 | -34,087 | -33% | $32.27 | 70,195 | 01 Nov 2021 | Direct | F1, F2 |
| transaction | ANAB | Common Stock | Sale | $84,139 | -2,559 | -3.6% | $32.88 | 67,636 | 01 Nov 2021 | Direct | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANAB | Employee Stock Option (right to buy) | Options Exercise | $0 | -36,646 | -50% | $0.000000 | 36,645 | 01 Nov 2021 | Common Stock | 36,646 | $1.12 | Direct | F4, F5 |
| Id | Content |
|---|---|
| F1 | The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.84 to $32.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.85 to $32.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| F4 | The stock option grant was issued on January 31, 2012 and became fully vested as of January 31, 2016, and is exercisable until its expiration date of January 31, 2022. |
| F5 | In addition to the remaining options to purchase 36,645 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,139,254 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly. |